Alembic Pharma Gets USFDA Nod for Acyclovir Ointment
Alembic Pharma said it has received approval from the USFDA for its abbreviated new drug application (ANDA) for Acyclovir ointment USP, 5 per cent. The ointment is used for the treatment of genital herpes. The approved ointment is therapeutically equivalent to the reference listed drug product (RLD) Zovirax ointment 5 per cent of Valeant Pharmaceuticals North America LLC. As per IMS data, for twelve months ending December 2016, the ointment has an estimated market size of $145-mn.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-06-19
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pharma Quality Excellence Awards 2026 - Celebration and Conclusion
-
Pharma Quality Reimagined: Highlights from the 6th Annual Pharma GMP & Quality Management 2026
-
From Feedmill to Food System: VIV Europe 2026 Addresses the Industry's Most Critical Challenges
-
Beyond Compliance: Building Quality Maturity
-
Is the class solidified? From Biotech to Pharma
-
The IPO of the Largest Domestic Metronidazole API Manufacturer has Passed the Meeting
-
Progesterone Market Potential is Huge
-
PharmaReg AfriSummit
-
2022 PHARMA X FOOD X FINE CHEMICAL RAW MATERIALS MATCH MEETING Successfully Held!
-
KOREA PHARM & BIO 2021
Recommend Reading
-
Haryana’s Drug Crackdown Gets Massive Public Support State Launches Podcast to Boost Community Involvement
-
Wall Street Predicts New Obesity Pills Will Be Priced Near $1000 Like Wegovy and Zepbound Supply and Competition Pressures Mount
-
Glenmark Targets 10–15 Percent CAGR in India by Shifting to High-Margin Drugs AbbVie Deal and New Launches Boost Outlook
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
Toray Supplies Reverse Osmosis Membranes to Saudi Arabian Desalination Plant
-
Global MDI/TDI Plants Enter Peak Maintenance Season, Wanhua Chemical’s Hungary Shutdown Draws Market Attention
-
Europe Faces Unprecedented Petrochemical Crisis 50,000 Jobs at Risk as Closures Accelerate
-
Sekisui Specialty Chemicals Has Announced a Global Price Increase
-
Wanhua Chemical’s 2025 Revenue Exceeds RMB 200 Billion While Net Profit Remains Under Pressure